No Picture
PR Newswire

Audentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM

Study intended to serve as longitudinal baseline and within-patient control for ASPIRO, the planned Phase 1/2 study of AT132 for the treatment of XLMTM

SAN FRANCISCO, Aug. 17, 2016 /PRNewswire/ — Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported that the first patient has been enrolled in INCEPTUS, a prospective study designed to characterize the disease presentation in children living with X-Linked Myotubular Myopathy (XLMTM). The study is evaluating subjects prior to potential enrollment in ASPIRO, the planned Phase 1/2 clinical study intended to evaluate the safety and preliminary efficacy of AT132, the Audentes product candidate for treatment of XLMTM.

“The initiation of enrollment for INCEPTUS is an important first step in the clinical development of AT132 for the treatment of XLMTM and a notable milestone for Audentes,” stated Dr. Suyash Prasad, Audentes Senior Vice President and Chief Medical Officer. “The burden of the disease of XLMTM to children and families is considerable, and we are grateful to those who have agreed to participate in the study,” concluded Dr. Prasad.

INCEPTUS is an international study of boys with XLMTM, ages three years or younger, designed to characterize their individual disease presentation, with a specific focus on respiratory measurements and assessment of muscle strength and function. Patients enrolled in INCEPTUS will be evaluated over a three to twelve-month period prior to their potential participation in ASPIRO. INCEPTUS is designed to serve as a longitudinal baseline and within-patient control for subjects who enroll in the ASPIRO study, while also facilitating the operational aspects of ASPIRO once initiated.  

Audentes plans to file investigational new drug applications for AT132 with North American and European regulatory authorities in the first quarter of 2017. The company expects preliminary data from the ASPIRO study in the fourth quarter of 2017.

For additional information on INCEPTUS, please visit www.clinicaltrials.gov.

About X-Linked Myotubular Myopathy (XLMTM)

X-Linked Myotubular Myopathy (XLMTM) is a rare, inherited disorder characterized by severe muscle weakness, respiratory impairment and early mortality. There is no approved treatment for the condition. It is caused by mutations in the MTM1 gene, which encodes a protein called myotubularin. Myotubularin plays an important role in the development, maintenance and function of skeletal muscle cells. XLMTM affects approximately 1 in 50,000 newborn males worldwide. Audentes is developing AT132 for the treatment of XLMTM in collaboration with Genethon (www.genethon.fr). AT132 is a novel product based on AAV gene therapy technology.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s anticipated clinical development and regulatory activities and the timing of clinical results. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercial its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other  risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Audentes Contacts:

Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com

Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com

Logo – http://photos.prnewswire.com/prnh/20160719/391266LOGO

 

SOURCE Audentes Therapeutics, Inc.

[…]

No Picture
PR Newswire

Ambrx’s Innovative Antibody Drug Conjugate (ADC) US IND Active

SAN DIEGO, Aug. 17, 2016 /PRNewswire/ — Ambrx announced today that their ARX788 US IND is now active. ARX788 is Ambrx’s most advanced internally developed site-specific ADC targeting Her2. Ambrx ARX788 may hold the potential for a broader patient population than the currently available Her2-targeting therapies. Ambrx will open US sites for the first-in-human (FIH) study which is currently recruiting patients at several sites in Australia and New Zealand. The primary end point is safety and tolerability. The pharmacokinetics and antitumor activity of ARX788 will also be evaluated.

“The opening of the US IND for ARX788 represents an important milestone for Ambrx to advance the development of this innovative ADC drug in the world market, such as the US, in addition to China and other regions,” said Alex Qiao, Chief Executive Officer of Ambrx. “This will help us accelerate the development timeline for ARX788 which will provide clinical validation of our proprietary EuCODE technology for the improvement of cancer patient lives.”

About Ambrx
Ambrx®, Inc. is a clinical stage biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry.

The company is developing ARX788 – a site-specific antibody drug conjugate for breast cancer and gastric cancer. In addition to its ADC collaborations with Astellas, Bristol-Myers Squibb and Zhejiang Medicine Co. Ltd, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly and Hisun. Ambrx is developing a robust portfolio of product candidates that are optimized for efficacy and safety in oncology.

At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines. For additional information, visit www.ambrx.com.

Logo – http://photos.prnewswire.com/prnh/20151110/285915LOGO

 

SOURCE Ambrx, Inc.

[…]

No Picture
PR Newswire

Xycrobe Announces Research Collaboration with Johnson & Johnson Innovation

LA JOLLA, Calif., Aug. 16, 2016 /PRNewswire/ — Xycrobe Therapeutics announced today that it has entered into a research agreement with Johnson & Johnson Consumer, Inc. The collaboration, facilitated by Johnson & Johnson Innovation, is focused on further understanding applications of Xycrobe’s platform technology developed for the treatment of inflammatory skin diseases. The planned collaboration is intended to provide both companies with information on how the Xycrobe technology may be best applied to future therapeutic and commercial applications.

Xycrobe’s technology consists of a library of commensal strains from the skin microbiome engineered to grow and secrete biotherapeutics as needed to help treat an array of skin issues.

“The current paradigm for treating skin conditions, such as acne, completely disregards the importance of the commensal skin flora. Overuse of antibiotics have led to a higher prevalence of resistant strains of bacteria and along with that comes less efficacy for conventional treatments. So, we are attempting to change that paradigm,” said Thomas Hitchcock, Ph.D., Founder and CEO of Xycrobe. “We feel that the key to better treatment solutions for skin disease lies in understanding our body’s interaction with the skin microbiome, and how we can leverage this information. I am thrilled that Johnson & Johnson Consumer has elected to join us in our discovery process, and it is our hope that this collaboration can help expedite getting our therapies into the hands of physicians and their patients who truly need better solutions.”

Xycrobe has developed several strains of commensal skin bacteria that show potential for the significant reduction of inflammation, promising potential relief from ailments such as acne, psoriasis, dermatitis and eczema.

“As Medical Director, and as a dermatologist, I am excited to hear about this collaboration between Xycrobe and Johnson & Johnson Consumer, Inc.,” said Hilary Baldwin, M.D. of the Acne Treatment Research Center. “We try to keep our fingers on the pulse of what is being developed in the acne space, and have been following Xycrobe’s progress since early on. Xycrobe’s innovative technology and approach has great potential to change the way we think about how we treat acne and it’s good to see a big player working with this emerging company.”

While Xycrobe intends to explore programs that address a variety of skin issues ranging from hair loss to toenail fungus, their current focus is on inflammatory skin diseases such as acne, psoriasis and dermatitis. These conditions affect over 100 million people in the US alone, and are not effectively addressed by the therapies currently on the market. Xycrobe seeks to address this large need through development of their platform technology.

ABOUT XYCROBE THERAPEUTICS, INC.

Xycrobe Therapeutics, Inc. is the developer of an innovative, microbial-delivery-system platform technology that can distribute an array of biotherapeutics directly to target tissues, to substantially improve health and quality-of-life. Leveraging the vast amount of data being generated from human microbiome research, Xycrobe is currently developing novel therapies for a variety of clinical applications. Xycrobe is currently a resident company at JLABS San Diego. For more information, please visit http://www.xycrobe.com.

 

 

SOURCE Xycrobe Therapeutics, Inc.

[…]

No Picture
PR Newswire

Agena Bioscience Expands ISO Accreditation for Genetic Testing

SAN DIEGO, Aug. 16, 2016 /PRNewswire/ — Agena Bioscience today announced accreditation of its Assays by Agena facility in Brisbane, Australia, under ISO/IEC 17025 in the field of biological testing for determinations of SNP Genotyping, somatic mutation detection, and quantitative methylation analysis using its MassARRAY® System.

The accreditation comes from the National Association of Testing Authorities, or NATA, and ensures that member facilities comply with standards and provide accurate data generation, controlled test methods and procedures, and properly trained personnel.

Agena Bioscience CEO Peter Dansky commented, “Accreditation of our facility in Brisbane demonstrates the company’s commitment to advance the MassARRAY System into the clinical market, and ensure consistent, valid, and robust results under documented quality management systems.”

The Assays by Agena facility in Brisbane offers highly cost-effective and adaptive testing services and custom panel development. In particular, the facility will offer a multiplexed solution for detecting rare variants in liquid biopsies as low as 0.1% frequency. “Detection of rare variants in tissue biopsies and minimally invasive liquid biopsies is a rapidly emerging field, well suited to the accuracy, sensitivity, flexibility and short turnaround time of the MassARRAY System. This enables valuable insight into genetic changes that may occur during the course of diseases such as cancer,” Dansky elaborated.

The ISO/IEC 17025 accreditation follows the company’s success in achieving significant milestones to enter the clinical diagnostics market. Earlier this year, Agena Bioscience launched two CE-IVD marked MassARRAY diagnostic products for in vitro testing of colon and lung tumors. The company previously received ISO/IEC 13485 certification of its San Diego facilities to develop, manufacture, and distribute its MassARRAY System, software, and reagents for life sciences.  

About Agena Bioscience

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. In the United States, the MassARRAY System is intended for research use only, and not intended for use in diagnostic procedures.
www.agenabioscience.com

Logo – http://photos.prnewswire.com/prnh/20150324/194277LOGO

 

SOURCE Agena Bioscience

[…]

No Picture
PR Newswire

IndieBio Partners with Elemental Machines for Contextual Monitoring of Lab Environment

Smart Lab System Helps Participating Entrepreneurs Improve Experimental Research with New Data Streams and Insights

SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 16, 2016 /PRNewswire/ — Elemental Machines, provider of intelligent technology for the smart lab, and IndieBio SF, the world’s premiere Synthetic Biology accelerator, today announced a partnership for participants to have access to the Elemental Machines Suite of products to enhance their experimental research work.

With a commitment to building a future where biology is considered technology that will help solve our culture’s most challenging problems, IndieBio offers funding, mentorship and lab space to a select group of entrepreneurs in each class, including the 15 that presented at the recent IndieBio SF Demo Day. Elemental Machines provides a portfolio of products that help researchers streamline their work, refine protocols, and improve experimental reproducibility, which is one of the most significant challenges researchers face.

“Our companies work in a highly compressed time frame to prove the viability of their research as a platform for building scalable, high-impact businesses,” said Ron Shigeta, IndieBio’s Chief Scientific Officer. “We are delighted to use Elemental Machines products to support our teams’ work as it is helping save time and improve outcomes and yields.”

The Elemental Machines products deployed at IndieBio include Elements, credit-card-sized, intelligent, wireless, sensor-rich devices that track and record physical conditions in the laboratory and inside key equipment, and Elemental Insights, a web-based dashboard that provides real-time data visualizations and alerts. Given that temperature, light and humidity are three variables that can greatly influence bio/chemistry, having real-time access to such data in the lab and also detailed insight into the performance of instruments (e.g. refrigerators, freezers, and incubators), researchers have visibility into how these contextual variables can affect their work.

“Monitoring the precise conditions within our growing environment has been one of our highest priorities as we optimize the production environment for our healthy and sugar-free protein sweeteners,” said Alan Perlstein, CEO and Founder of MiraculeX, one of the recent IndieBio program participants. “Access to Elemental Machines’ products has helped us accelerate our development, putting us on track to roll out our first product by the end of this year.” 

“Every scientist knows that many of the reproducibility issues in biology and chemistry can be traced to factors in the physical world,” said Sridhar Iyengar, CEO of Elemental Machines. “We are honored to be working with the IndieBio team and their startups — the next generation of synthetic biology innovators and entrepreneurs.”

About Indie.Bio and SOSventures
IndieBio SF is funded by SOSV, “The Accelerator VC,” and is devoted to funding and building biotech startups dedicated toward solving humanity’s most pressing problems with life itselfSOSV accelerates startups with mentoring and finance. They run unique, high-value accelerator programs that we believe provide great value to entrepreneurs, serving and supporting them with breakthrough mentoring, world-class demo days, and distribution and sales assistance.

About Elemental Machines
Elemental Machines is accelerating scientific discovery with a powerful application suite for improving experimental reproducibility. With offices in Cambridge, MA and Burlingame, CA the company is led by an accomplished entrepreneurial team committed to addressing some of the scientific community’s biggest challenges. For more information, please visit www.elementalmachines.io.

Logo – http://photos.prnewswire.com/prnh/20160202/328603LOGO

SOURCE Elemental Machines

[…]

No Picture
PR Newswire

Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline

SAN DIEGO, Aug. 15, 2016 /PRNewswire/ — Scintilla Pharmaceuticals, Inc. (“Scintilla”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), has entered into a binding term sheet to acquire Semnur Pharmaceuticals, Inc. (“Semnur”). Scintilla’s lead program is resiniferatoxin (“RTX”) for the treatment of intractable cancer pain.

Semnur, based in Los Altos, CA, is a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients. Semnur’s lead product, projected to commence Phase 3 clinical trials in 2017, is a non-opiate epidural steroid injectable to treat chronic back pain.  Key members of Semnur’s management team are expected to join Scintilla’s management team. On August 8, 2016, Scintilla announced it had entered into a binding term sheet to acquire SCILEX Pharmaceuticals, Inc. (“SCILEX”).  Following the closing of the announced acquisitions Scintilla will operate as a stand-alone company focused on pain management.

The acquisition is contingent upon customary closing conditions. In consideration for the acquisition, Scintilla will pay Semnur’s equity holders an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of common stock of Sorrento.  In addition, additional cash consideration of up to $140 million may be paid by Scintilla to Semnur’s equity holders upon achievement of certain development, product approval and commercial milestones.  Joseph Gunnar & Co., LLC provided a fairness opinion to Sorrento, as the majority stockholder of Scintilla.  

“Semnur represents a unique asset for Scintilla that is highly complementary to its existing assets.  Semnur’s pipeline of multiple late-stage and near commercialization product opportunities targets some of the largest pain markets available and addresses critical unmet medical needs,” said Dr. Henry Ji, President and CEO of Sorrento.  Dr. Ji further added, “upon completion of the pending acquisitions and integrations of Semnur and SCILEX, Scintilla will immediately become a truly unique pain management company with a multiple product pipeline and an experienced management team led by Jaisim Shah from Semnur and Anthony Mack from SCILEX.”

“The acquisition by Scintilla reflects the strength of Semnur’s technology, IP and tremendous potential of our lead product candidate,” stated Mahendra Shah, Executive Chairman of Semnur Pharmaceuticals, Inc. and Managing Director of Vivo Capital. “We are excited to join Scintilla and be a part of such a dynamic company that will be a major player in the pain management space,” added Mr. Shah.

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

About Scintilla Pharmaceuticals, Inc.

Scintilla Pharmaceuticals, Inc. is a subsidiary of Sorrento Therapeutics, Inc. Scintilla’s lead program is RTX for the treatment of opiate refractory cancer pain.  The RTX program has been tested successfully in a Phase 1 – 2 clinical trial, and is scheduled to commence Phase 2 clinical trials in early 2017.

About Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients.  Semnur’s primary focus lies in the development of non-opioid products for meeting the needs of underserved patients with back pain. Semnur believes that the therapeutic advantages of their product and technology will improve products’ efficacy and safety making a substantial improvement in the treatment of back pain.

About SCILEX Pharmaceuticals, Inc.

SCILEX Pharmaceuticals, Inc., located in Malvern, PA, develops and brings branded pharmaceutical products to market using technologies that are designed to maximize quality of life for all.  SCILEX is working to deliver the next generation of products that are responsible by design. The Company’s lead product candidate under development, ZTlido™ (lidocaine patch 1.8%), is a branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information, visit www.scilexpharma.com.  ZTlido™ is a trademark owned by SCILEX Pharmaceuticals, Inc.  A proprietary name review by the FDA is planned.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the proposed acquisitions of Semnur and SCILEX and the timing and potential benefits of the transactions; expectations regarding Scintilla’s, Semnur’s and SCILEX’s technologies; expectations for Sorrento’s and its subsidiaries technologies and collaborations; expectations regarding the commencement of Phase 2 clinical trials for Scintilla’s RTX program; and Scintilla’s prospects.  Expectations regarding the timing of the Phase 3 clinical trials for Semnur’s lead product candidate. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’ technologies and prospects; risks related to the completion of the proposed acquisitions of Semnur and SCILEX; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2015, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.  Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics, Inc.  All Rights Reserved.

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO

 

SOURCE Sorrento Therapeutics, Inc.

[…]

No Picture
PR Newswire

Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development

SAN DIEGO, Aug. 15, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; “Celgene”), has been appointed to the position of Chief Medical Officer and President of Clinical Development.

Dr. Jerome (“Jerry”) Zeldis joins Sorrento after a nearly 20-year career at Celgene during which he was instrumental in growing Celgene into one of the leading global biopharmaceutical companies.   Most recently, Dr. Zeldis held the position of Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene. In that capacity, Dr. Zeldis oversaw clinical trials using Celgene’s molecules.  Prior to Celgene, Dr. Zeldis was the Associate Director of Clinical Research at Sandoz Research Institute and the Director of Medical Development at Janssen Pharmaceutical Research Institute.

Dr. Zeldis received his medical training in Internal Medicine at the UCLA Center for the Health Sciences and was a clinical and research fellow in gastroenterology at Massachusetts General Hospital and Harvard Medical School.  Additionally, he served as an Assistant Professor of Medicine at Harvard Medical School, an Associate Professor of Medicine at the University of California, a Clinical Associate Professor of Medicine at Cornell Medical School, and a Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, NJ. Dr. Zeldis holds BA and MS degrees from Brown University, and M.Phil., M.D., and Ph.D. degrees from Yale University.  Dr. Zeldis has published 122 peer-reviewed articles and is a named inventor on 43 US patents. He currently serves as Chairman of the board of Alliqua, Semorex, and Trek Therapeutics, Vice Chairman of MetaStat and serves on the boards of Kalytera Therapeutics, BioSig Technologies, IR Biosciences Holdings, PTC Therapeutics, and Soligenix.

“We are thrilled to have a highly accomplished biotech veteran of Jerry’s stature join Sorrento to guide, drive and accelerate our clinical development,” said Dr. Henry Ji, President & CEO of Sorrento. “His expertise and track record in highly successful drug development will be invaluable to progress the clinical development of our program pipeline towards FDA approval and commercialization. Jerry’s appointment highlights our focus on investing in clinical development and our steadfast commitment to Sorrento shareholders following the recent $150 million private placement led by Ally Bridge Group completed in June of this year.”

Dr. Zeldis stated, “Sorrento has an impressive portfolio of unique assets that I believe will clearly differentiate themselves in addressing unmet medical needs in a multitude of markets.  I greatly look forward to joining the team that is growing Sorrento into a leading biopharmaceutical company and using my experience to build a world-class clinical and regulatory organization for the efficient, high-quality clinical development of Sorrento’s cutting-edge immunotherapies.”

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases. Sorrento’s lead products are late-stage biosimilar and biobetter antibodies, RTX for intractable cancer pain, as well as clinical CAR-T and CAR-NK therapies targeting solid tumors.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento’s and its subsidiaries’ technologies and collaborations; Sorrento’s ability to leverage the expertise of its employees and partners to assist the company in the execution of its strategies; and Sorrento’s prospects.  Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’ technologies and prospects; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2015, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics, Inc.  All Rights Reserved.

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO

 

SOURCE Sorrento Therapeutics, Inc.

[…]